Committee Members
Marie Bleakley, MD, PhD, M.MSC
Dr. Bleakley is a pediatric hematologist-oncologist who specializes in hematopoietic (blood-forming) stem cell transplantation and T cell immunotherapy for patients with leukemia and other blood cancers.
Jarrod Dudakov, PhD
Dr. Dudakov studies how the immune system naturally recovers after damage, such as from common cancer therapies like chemotherapy and radiation.
Lawrence Fong, MD
Dr. Fong researches the mechanisms of response and resistance to cancer immunotherapies in both preclinical models and in cancer patients. A physician-scientist, his work helped lead to approval by the U.S. Food and Drug Administration (FDA) of sipuleucel-T, an immunotherapy for prostate cancer.
Geoffrey Hill, MD, FRACP, FRCPA
Dr. Hill is a physician-scientist who specializes in blood stem cell transplantation. He is one of the top authorities on the transplant complication known as graft-vs.-host disease, or GVHD.
Hans-Peter Kiem, MD, PhD
Dr. Kiem is a world-renowned pioneer in stem-cell and gene therapy and in the development of new gene-editing technologies.
Filippo Milano, MD, PhD
Dr. Milano is a physician-scientist whose research is focused on the use of umbilical cord blood as a source of stem cells for transplantation to treat blood cancers.
Folashade Otegbeye, MBChB, MPH
Dr. Otegbeye is a clinical researcher who specializes in blood stem cell transplantation for blood cancers and other diseases of blood and marrow. In her role as facility director of Fred Hutch’s Therapeutic Products shared resource, she works with Fred Hutch’s cellular immunotherapy labs to translate their research ideas into clinical products.
Aaron Ring, MD, PhD
Dr. Ring works at the intersection of protein engineering and systems immunology to identify new therapeutic targets for cancer and to create drugs against them. His work has resulted in the development of several innovative cancer therapeutics now being tested in clinical trials, including engineered cytokines and immune receptors.
Brenda Sandmaier, MD
Dr. Sandmaier’s goal is to extend the benefits of transplant immunotherapy to a broader range of patients, including hematopoietic cell transplant patients who are older or have medical complications, and those who don’t have donors with complete genetic matches.
Mazyar Shadman, MD, MPH
Dr. Shadman is a blood cancer specialist who focuses on lymphoid malignancies. He is involved in clinical research using novel therapeutic agents for lymphoma and chronic lymphocytic leukemia, or CLL, as well as immunotherapy (specifically CAR T cell therapy) for lymphoid neoplasms and blood stem cell transplant for hematologic malignancies.
Masumi Ueda Oshima, MD, MA
Dr. Ueda Oshima treats patients with leukemia, myelodysplastic syndrome and graft-vs.-host-disease. She specializes in blood stem cell and bone marrow transplantation. Her clinical research focus is on the prevention of graft-vs.-host disease.
Paul G. Thomas, PhD
Dr. Thomas is a viral immunologist with a focus on respiratory viruses. He integrates quantitative, computational and empirical methods to understand how our immune systems respond to infection. Dr. Thomas focuses immune regulation of health and disease, including tissue injury during infection, cancer development and resolution, and effective anti-pathogen responses.